XML 32 R18.htm IDEA: XBRL DOCUMENT v3.19.1
Note 11 - Other Accrued Liabilities
12 Months Ended
Dec. 31, 2018
Notes to Financial Statements  
Other Liabilities Disclosure [Text Block]
11—OTHER
ACCRUED LIABILITIES
 
Other accrued liabilities consist of the following:
 
    December 31,
    2018   2017
Retirement indemnities    
2,287
     
2,076
 
Provision for warranty costs    
547
     
449
 
Accruals for payroll and associated taxes    
680
     
611
 
Conditional government advances    
1,039
     
1,039
 
Value added tax payable    
327
     
125
 
Advances received from customers    
115
     
108
 
Provision for Asset Retirement Obligation (Japan)    
118
     
100
 
Provision for employee termination indemnities (Italy)    
369
     
349
 
Provision for employee termination indemnities (Korea)    
30
     
 
Others    
411
     
360
 
Total    
5,923
     
5,217
 
Less non-current portion    
(3,800
)    
(3,681
)
Current portion    
2,122
     
1,536
 
 
We receive government conditional advances and grants for advanced research programs we conduct alone or in connection with other unrelated entities (mainly HECAM project) which are provided for and managed by French state-owned entities, and specifically “Banque Publique d’Investissement” (“Bpifrance”). We, alone or with other unrelated entities, enter into multi-year contractual arrangements for the financing of specific research programs. These arrangements consist of both grants and conditional advances which are paid in fixed instalments at predetermined contractual dates, subject generally to milestones based on progress of the research and documentation. Grants received are non-refundable. Conditional advances received are subject to a fixed
1.44%
interest rate. If and when the research program is considered a commercial success, contractual repayment is required. In addition, if we decide to stop the research program, the conditional advance
may
be repayable. Grants that relate to expenses we incur for this research program are recognized in the line item “Research and Development Expenses” in the period in which the expenses subject to the grants have been incurred (see Note
20
).
 
Conditional advances as of
December 31, 2018,
mature as follows, should the underlying Research Program advance as per contract:
 
2019    
 
2020    
 
2021    
 
2022    
203
 
2023 and thereafter    
836
 
Total    
1,039
 
 
Changes in the provision for warranty costs are as follows:
 
    December 31,
    2018   2017
Beginning of year    
449
     
548
 
Amount used during the year    
(335
)    
(415
)
New warranty expenses    
433
     
316
 
End of year    
547
     
449
 
Less current portion    
(356
)    
(265
)
Long term portion    
191
     
184